The estimated Net Worth of Randal J Kirk is at least $153 Milión dollars as of 9 August 2024. Mr. Kirk owns over 23,529,411 units of Precigen Inc stock worth over $62,610,798 and over the last 17 years he sold PGEN stock worth over $88,624,666. In addition, he makes $2,067,620 as Executive Chairman of the Board at Precigen Inc.
Randal has made over 89 trades of the Precigen Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he bought 23,529,411 units of PGEN stock worth $19,999,999 on 9 August 2024.
The largest trade he's ever made was buying 23,529,411 units of Precigen Inc stock on 9 August 2024 worth over $19,999,999. On average, Randal trades about 461,572 units every 25 days since 2007. As of 9 August 2024 he still owns at least 64,547,214 units of Precigen Inc stock.
You can see the complete history of Mr. Kirk stock trades at the bottom of the page.
Randal J. Kirk serves as Executive Chairman of the Board of the Company. Mr. Kirk has served as Executive Chairman of the Board since January 2020 and previously served as Chairman of the Board from February 2008 until January 2020 and as our CEO from April 2009 until January 2020. Mr. Kirk provides a wealth of strategic, operational, and management experience. Mr. Kirk currently serves as the Senior Managing Director and CEO of Third Security, LLC, an investment management firm founded by Mr. Kirk in March 1999. Additionally, Mr. Kirk founded and became Chairman of the Board of New River Pharmaceuticals Inc. (a biopharmaceutical company previously traded on Nasdaq prior to its acquisition by Shire plc in 2007) in 1996, and was President and CEO between October 2001 and April 2007. Since May 2015, Mr. Kirk has served as a member of the board of directors of the Edward Via College of Osteopathic Medicine. Previously, Mr. Kirk served as a member of the board of directors of Scios, Inc. (previously traded on Nasdaq prior to its acquisition by Johnson & Johnson) between February 2000 and May 2002, as a member of the board of directors of Halozyme Therapeutics, Inc. (Nasdaq: HALO), a clinical stage biotechnology company, from May 2007 to May 2018, as a member of the board of directors of ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biotechnology company, from January 2011 to October 2018, and as a member of the board of directors of Clinical Data, Inc. (previously traded on Nasdaq prior to its acquisition by Forest Laboratories, Inc. in April 2011) from September 2002 to April 2011, and was Chairman of the board of directors from December 2004 to April 2011. Mr. Kirk served on the board of visitors of Radford University from July 2003 to June 2009, was Rector of the board of directors from September 2006 to September 2008 and served on the board of directors of the Radford University Foundation, Inc. from September 1998 to May 2011.
As the Executive Chairman of the Board of Precigen Inc, the total compensation of Randal Kirk at Precigen Inc is $2,067,620. There are no executives at Precigen Inc getting paid more.
Randal Kirk is 66, he's been the Executive Chairman of the Board of Precigen Inc since 2020. There are 4 older and 14 younger executives at Precigen Inc. The oldest executive at Precigen Inc is Robert Shapiro, 81, who is the Lead Independent Director.
Randal's mailing address filed with the SEC is 1881 Grove Ave, Radford, VA 24141, USA.
Over the last 5 years, insiders at Precigen Inc have traded over $44,216,787 worth of Precigen Inc stock and bought 52,689,457 units worth $114,197,137 . The most active insiders traders include Randal J Kirk, Trading S.A. Ares a Helen Sabzevari. On average, Precigen Inc executives and independent directors trade stock every 9 days with the average trade being worth of $358,866. The most recent stock trade was executed by Randal J Kirk on 9 August 2024, trading 23,529,411 units of PGEN stock currently worth $19,999,999.
precigen, inc. discovers and develops the next generation of gene and cellular therapies in the united states. it also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. in addition, the company offers ultravector platform that incorporates advanced dna construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbil15, a gene that enhances functional characteristics of immune cells; sleeping beauty, a non-viral transposon/transposase system; attsite recombinases, which breaks and rejoins dna at specific sequences; adenoverse technology platform, a library of engineered adenovector serotypes; and l. lactis is a food-grade bacterium. additionally, it provides rheoswitch inducible gene switch that provides qua
Precigen Inc executives and other stock owners filed with the SEC include: